SCHEMBL4054859

SCHEMBL4054859

O=C(c1ccccc1)c1ccc(-c2nc3ncc(-c4ccco4)cc3[nH]2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 6/20 0.54
IKBKE Q14164 5/20 0.54
AURKA O14965 2/20 0.48
CHEK2 O96017 3/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.46
BLM P54132 1/20 0.46
MCL1 Q07820 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PRMT5 O14744 1/20 0.43
HDAC6 Q9UBN7 1/20 0.41
KIT P10721 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4050957 0.87 IKBKE (0.49) TBK1IKBKEAURKAKDM4EUSP2
SCHEMBL4058876 0.85 AURKA (0.59) TBK1IKBKEAURKACHEK2MEN1
SCHEMBL13608047 0.83 MAPT (0.49) CHEK2MEN1KMT2AKDM4EUSP2
SCHEMBL4059593 0.82 IKBKE (0.47) TBK1IKBKEAURKAKDM4EALDH1A1
SCHEMBL4062911 0.81 IKBKE (0.48) TBK1IKBKEAURKACHEK2KDM4E
SCHEMBL4059275 0.79 AURKA (0.58) AURKACHEK2MEN1KMT2AKDM4E
SCHEMBL4056737 0.79 SCD (0.59) TBK1IKBKEAURKACHEK2KMT2A
SCHEMBL4055484 0.79 TBK1 (0.66) TBK1IKBKEAURKAKDM4EALDH1A1
SCHEMBL4055492 0.78 TBK1 (0.53) TBK1IKBKEAURKACHEK2KDM4E
SCHEMBL4052283 0.77 DHODH (0.47) TBK1IKBKEAURKACHEK2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B TBK1 1212/4885IKBKE 129/4885AURKA 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.